key: cord-1037623-myu6dqlu
authors: Ferrari, Mathieu; Mekkaoui, Leila; Ilca, F. Tudor; Akbar, Zulaikha; Bughda, Reyisa; Lamb, Katarina; Ward, Katarzyna; Parekh, Farhaan; Karattil, Rajeev; Allen, Christopher; Wu, Philip; Baldan, Vania; Mattiuzzo, Giada; Bentley, Emma M.; Takeuchi, Yasuhiro; Sillibourne, James; Datta, Preeta; Kinna, Alexander; Pule, Martin; Onuoha, Shimobi C.
title: Characterization of a Novel ACE2-Based Therapeutic with Enhanced Rather than Reduced Activity against SARS-CoV-2 Variants
date: 2021-09-09
journal: J Virol
DOI: 10.1128/jvi.00685-21
sha: 748bf25b7c48be828a941ed27e31aa281e46128f
doc_id: 1037623
cord_uid: myu6dqlu

The human angiotensin-converting enzyme 2 acts as the host cell receptor for SARS-CoV-2 and the other members of the Coronaviridae family SARS-CoV-1 and HCoV-NL63. Here, we report the biophysical properties of the SARS-CoV-2 spike variants D614G, B.1.1.7, B.1.351, and P.1 with affinities to the ACE2 receptor and infectivity capacity, revealing weaknesses in the developed neutralizing antibody approaches. Furthermore, we report a preclinical characterization package for a soluble receptor decoy engineered to be catalytically inactive and immunologically inert, with broad neutralization capacity, that represents an attractive therapeutic alternative in light of the mutational landscape of COVID-19. This construct efficiently neutralized four SARS-CoV-2 variants of concern. The decoy also displays antibody-like biophysical properties and manufacturability, strengthening its suitability as a first-line treatment option in prophylaxis or therapeutic regimens for COVID-19 and related viral infections. IMPORTANCE Mutational drift of SARS-CoV-2 risks rendering both therapeutics and vaccines less effective. Receptor decoy strategies utilizing soluble human ACE2 may overcome the risk of viral mutational escape since mutations disrupting viral interaction with the ACE2 decoy will by necessity decrease virulence, thereby preventing meaningful escape. The solution described here of a soluble ACE2 receptor decoy is significant for the following reasons: while previous ACE2-based therapeutics have been described, ours has novel features, including (i) mutations within ACE2 to remove catalytical activity and systemic interference with the renin/angiotensin system, (ii) abrogated FcγR engagement, reduced risk of antibody-dependent enhancement of infection, and reduced risk of hyperinflammation, and (iii) streamlined antibody-like purification process and scale-up manufacturability indicating that this receptor decoy could be produced quickly and easily at scale. Finally, we demonstrate that ACE2-based therapeutics confer a broad-spectrum neutralization potency for ACE2-tropic viruses, including SARS-CoV-2 variants of concern in contrast to therapeutic MAb.

SARS-CoV-2 S1 (Commercial) SARS-CoV-2 S1 Wuhan SARS-CoV-2 S1 D614G SARS-CoV-2 S1 B. % volume of total particles S1 Wuhan S1 D614G S1 B.1.1.7 S1 B.1.351 S1 (commercial) S1 P.1 S trimer and S1 domain by ELISA (Fig. 2E ). SPR measurements of kinetic interaction for the S1 domain of SARS-CoV-2 showed comparable kinetic profiles between active WT and HH:NN ACE2 (Table 1) , further suggesting the preservation of an unaltered spike binding domain.

Engineered Fc domain with abrogated FccR engagement. To overcome the risk of activating the host immune system, thus exacerbating the hyperinflammatory response often associated with severe COVID-19 development (28) , the Fc domain was engineered to remove FcgR interactions. The well-established L234A/L235A (LALA) (29) mutations of the CH2 domain and the LALA combination with P329G (LALA-PG) (30) were introduced in the human IgG1 Fc portion of the ACE2-Fc fusion protein. We first investigated the expression yields of the ACE2(HH:NN) with WT Fc, LALA Fc, and LALA-PG Fc and ACE2 domain activity. All constructs showed comparable expression and purification efficiencies using protein A affinity chromatography (data not shown). Mutations on the Fc domain did not affect the binding capacity of ACE2 for SARS-CoV-2 S protein, and all three versions showed highly comparable dose/response curves to recombinant SARS-CoV-2 S trimer or S1 domain by ELISA (Fig. 3A) . Similarly, all three variants were able to bind SupT1 cell lines expressing SARS-CoV-2 S trimer as a transmembrane protein (Fig. 3B ), further confirming binding capacity for the glycoprotein in a more physiological environment.

Next, we investigated the residual interaction of the engineered Fc domains for human FcgRI, FcgRII, and FcgRIII on K562, U937, and SupT1 human cell lines. K562 are (Fig. 3D ). Binding affinities of WT, LALA, and LALA-PG ACE2(HH:NN)-Fc variants for human Fcg Rs were tested via SPR. ACE2(HH:NN)-Fc showed strong interaction with FcgRIa and IIIa (27.5 nM and 73.2 nM, respectively) and reduced binding affinity for FcgRIIa and IIIb (207 nM and 118 nM, respectively). The LALA mutation still maintained residual binding to the FcgRIa and IIIa (657 nM and 225 nM, respectively) but no detectable binding to the remainder of the receptors. The LALA-PG mutation, however, showed a complete abrogation of FcgR binding, suggesting a more silent immunomodulatory profile (Fig. 3E) .

Analysis of ACE2 decoy cross-reactivity and spike binding affinity. As this receptor decoy has the potential to bind S glycoproteins of viruses that utilize ACE2 as host cell receptor, binding kinetics were generated for the S1 spike domain of SARS-CoV-1, SARS-CoV-2 Wuhan, D614G, B.1.1.7, B.1.351, and P.1 variants, and HCoV-NL63, comparing to the leading anti-SARS-CoV-2 antibodies LY-CoV555 (31), REGN10933, and REGN10987 (32) . The ACE2-Fc fusion constructs mediated specific interaction toward all spike proteins tested, while the monoclonal antibodies showed specificity for only the SARS-CoV-2 related S1 (Fig. 4A ). The ACE2(HH:NN)-Fc and ACE2(HH:NN)-Fc LALA-PG showed comparable affinities for the tested S1 domains, confirming no effect of the Fc mutations on ACE2 binding ( Fig. 4A and Table 1 ). Similar to the active ACE2-Fc, the inactive ACE2-Fc constructs also displayed an affinity enhanced 3-fold for the SARS-CoV-2 S1 B.1.1.7 and .2.5-fold for P.1. While the monoclonal antibody REGN10987 maintained a similar affinity for the SARS-CoV-2 S1 variants tested, with an almost 2-fold increase for the P.1 S1, the LY-CoV555 and REGN10933 were dramatically affected by the B.1.351 variant with 12-and 23-fold reduction in affinity compared to that of S1 Wuhan, respectively, and with a reduced impact, also by the P.1 variant ( Fig. 4A and Table 1 ).

Binding specificity and cross-reactivity of the ACE2(HH:NN)-Fc LALA-PG construct were assessed using a cell-based protein microarray assay, screening 5,477 full-length plasma membrane and cell surface-tethered human secreted proteins, 371 human heterodimers, and the SARS-CoV-2 S (Table S1 ). The test construct showed strong specific binding to the target protein SARS-CoV-2 S, while no other interaction was detected across the comprehensive panel of human protein (Fig. 4B ). An Fc LALA-PG only construct with the ACE2 domain omitted did not display any interaction with SARS-CoV-2 S or any other target tested. The control fusion protein CTLA4-hFc instead showed strong interaction for its predicted target CD86, and the FcgRIa, due to the presence of a WT IgG1 Fc domain. A secondary anti-human Fc antibody interaction with human IgG3 was detected across all conditions tested (Fig. 4B) .

In vitro neutralization of SARS-CoV-2 variants of concern. We first assessed the neutralization capacity of our decoy receptor against the authentic replication competent Next, to investigate the degree of neutralization efficiency against the SARS-CoV-2 variants of interest, the receptor decoy was tested against the engineered replicationdeficient lentiviral vectors pseudotyped with the glycoproteins of SARS-CoV-2 Wuhan, D614G mutation, B.1.1.7, and B.1.351 variants and SARS-CoV-1. The ACE2(HH:NN)-Fc LALA-PG was able to efficiently neutralize SARS-CoV-2, with tight dose-response curves among the SARS-CoV-2 variants, and SARS-CoV-1 (Fig. 4D) . Interestingly, the neutralization capacity was slightly improved for the B.1.1.7 and B.1.351 variants compared to that for SARS-CoV-2 Wuhan. The monoclonal antibody LY-CoV555 showed a marked reduction in neutralization capacity for the D614G and B.1.1.7 variants, 3-and 8-fold, respectively, significantly affecting the antibody efficacy, with an almost complete abrogation of neutralization against the B.1.351 variant (Fig. 4C ). The 1:1 REGN10933/ REGN10987 antibody cocktail was more resilient in its response to the SARS-CoV-2 variants but was characterized by a 4-fold reduction in neutralization for the B.1.351 variant. When the two antibodies constituting the cocktail were analyzed individually, the REGN10933 showed a 3-fold decrease in neutralization capacity for the D614G and B.1.1.7 variants, with a staggering .1,000-fold reduction for the B.1.351 variant, while the REGN10987 showed a 4-fold neutralization reduction for the B.1.1.7 variant and a 10-fold shift for the D614G variant (Fig. 4D) .

In vivo neutralization of SARS-CoV-2 in a hamster model of disease. It has been previously reported that hamsters are a relevant small animal model for SARS-CoV-2 infection, reporting symptoms such as reduced body weight and pathological lesions on the lung (33) . The hamster FcgRs show an interaction profile with human IgG1 Fc molecules different from that of hamster IgG Fc; nonetheless, the LALA-PG mutation of our construct still showed a complete lack of interaction with hamster FcgRs (Fig. 5A) . However, human Fc-tagged molecules are not expected to experience extended circulating half-life due to lack of hamster FcRn engagement. The pharmacokinetics of ACE2 (HH:NN)-Fc LALA-PG were assessed in healthy golden Syrian hamsters (Mesocricetus auratus) via intraperitoneal (i.p.) administration. The drug showed a half-life of 64.5 h and detectable levels up to 17 days postinjection for the 50 mg/kg dose (Fig. 5B) .

For in vivo SARS-CoV-2 neutralization, Syrian hamsters were challenged intranasally with 10 4.5 median tissue culture infectious dose (TCID 50 ) viral inoculum and then dosed 24 h later via i.p. injections of ACE2(HH:NN)-Fc LALA-PG at either 5 mg/kg or 50 mg/kg. Phosphate-buffered saline (PBS) injections were used for the placebo control group. The hamster groups treated with either high or low ACE2(HH:NN)-Fc LALA-PG doses showed a significant protection against body weight loss, with a maximum average weight loss of 11% compared to 21% for the placebo group, relative to the day of viral inoculum (Fig. 5C) . All groups showed a drastic reduction in motor activity with a trend for faster recovery in the two treated groups from day 5 post-viral challenge (Fig. 5D) . Throat swabs revealed a substantial reduction in viral RNA copies between day 4 and FIG 4 Legend (Continued) S1 domains. ACE2(HH:NN) Fc and ACE2(HH:NN) Fc LALA-PG were able to efficiently bind all spike protein tested. All sensograms were fitted with Langmuir 1:1 binding model, except for SARS-CoV-1 S1 kinetics, which were fitted with two-state kinetics. Twofold serial dilutions starting from 250 nM (500 nM for HCoV-NL63 S1). Journal of Virology day 6 compared to the viral load in the placebo; several animals showed undetectable levels of RNA between day 3 and day 6 for the high ACE2(HH:NN)-Fc LALA-PG dose and an overall viral load significantly lower than that of the placebo control group (Fig. 5E ). Generally, hamsters treated with the ACE2(HH:NN)-Fc (LALA-PG), especially at high dose, showed fewer clinical symptoms of disease, such as ruffled fur, body weight loss, and increased breathing, compared to those in the control group (Fig. 5F ). Macroanalysis on lung necropsies (day 7) also showed an overall reduction in lung damage for the ACE2(HH:NN)-Fc LALA-PG-treated groups, characterized by fewer lesions and blood clotting (Fig. 5G) . Finally, i.p. administered ACE2(HH:NN)-Fc LALA-PG was still detectable in the hamster sera at day 7, with levels for the high-dose treatment almost 20-fold higher than those for the low-dose treatment (Fig. 5H) . (Fig. 6A) . When tested in 20 mM His buffer, the first unfolding event occurred at a T m between 42.3 and 51.6°C, with the lowest T m associated with pH 3.5 and the most stable T m obtained at pH 6.5 (Fig. 6A) .

A crucial phase during manufacturing of monoclonal antibodies lies in the viral inactivation step, often carried out at low pH (36) , which can affect the stability and aggregation state of the proteins in solution. To investigate this, the ACE2(HH:NN)-Fc was exposed to pH 3.5 for 90 min before dialysis in 20 mM His pH 6.5. Thermal stability comparison of ACE2(HH:NN)-Fc at pH 3.5, 6.5, and 3.5 dialyzes to 6.5 showed how the initial instability due to pH 3.5 could efficiently be restored to that of the ACE2(HH:NN)-Fc following dialysis at pH 6.5 (Fig. 6B) . The distribution of particles within the solution showed a predominantly monodispersed profile for the ACE2(HH:NN)-Fc in PBS and 20 mM His pH 6.5, with an average diameter of 13.5 and 13.3 nm, respectively, in agreement with a molecule with a predicted molecular weight (MW) of 219 kDa. The suspension in a low pH buffer of 3.5 did not significantly enhance aggregation of ACE2(HH:NN)-Fc (Fig. 6C) . Furthermore, the change of buffer from PBS pH 7.4 to 20 mM His pH 6.5 and, crucially, the viral inactivation step at pH 3.5 with subsequent dialysis to pH 6.5 did not affect the capacity of the ACE2 (HH:NN)-Fc to bind the SARS-CoV-2 S1 protein, further validating the proposed process (Fig. 6D) .

The ACE2(HH:NN)-Fc LALA-PG also showed an increased thermal stability when in 20 mM His pH 6.5 buffer, with T m moving from 48.1°C to 52.0°C and CH2 CH3 unfolding happening at 64.3°C and 81.8°C, respectively (Fig. 6E) . The ACE2(HH:NN)-Fc LALA-PG was also characterized by a monodispersed particle profile with an average diameter size of 13.6 nm in 20 mM His pH 6.5 (Fig. 6F) . Finally, the formulation in 20 mM His pH 6.5 of ACE2(HH:NN)-Fc LALA-PG did not alter the SARS-CoV-2 neutralization capacity of the construct (data not shown).

We have described the generation of a catalytically inactive ACE2 receptor decoy fused to an engineered human Fc domain with abrogated FcgR engagement, showing optimal biophysical properties and manufacturability. The construct showed strong neutralization potency against several SARS-CoV-2 variants of concern in vitro and evidence of efficacy as a therapeutic administration in a live viral challenge model in vivo.

Monoclonal antibodies developed for the treatment of COVID-19 have shown efficacy in the treatment of early phases of the infection, potentially useful in prophylaxis or as an alternative for people who cannot be vaccinated (37) . However, cumulative S mutants may render therapeutic MAbs ineffective. For instance, the variants of concern B.1.351 and P.1 have been shown to affect the neutralization capacity of the approved antibody therapeutics. The LY-CoV555 antibody reported an almost complete abrogation of neutralization, while the antibody cocktail REGN-COV2 showed a severe impairment for one of its components, suggesting preservation of limited therapeutic efficacy (18, 19) . By analyzing kinetic of interactions, we determined that the antibodies LY-CoV555, REGN10933, and REGN10987 showed strong binding capacity for the SARS-CoV-2 Wuhan, D614G, and B.1.1.7 S1 domains. While not yet present in naturally occurring variants, the single amino acid mutation E406W has recently been shown to be able to escape both antibodies in the REGN-COV2 cocktail (38) , further highlighting the weakness of the MAb approach. "Receptor traps" are an established therapeutic approach, e.g., the anti-TNF Etanercept (20) , the VEGF-trap Aflibercept (21) , and the CTLA-4-Ig Abatacept (22) . Since ACE2, the receptor for SARS-CoV-2, is a type I transmembrane protein with a discrete extracellular domain, ACE2-based receptor decoys may be effective against COVID-19. A theoretical advantage of this approach is resistance to S mutational drift since mutations disrupting interaction with ACE2 would render the virus inactive. ACE2-based therapeutics have been described: A soluble catalytically active human ACE2 showed efficacy in the treatment of a severe COVID-19 patient by reducing plasma viremia (39) . Two recent reports have described engineered ACE2 molecules with sub nM affinities for the S glycoprotein (24, 26) . Similarly, ACE2-derived inhibitory peptides with improved manufacturability and stability also showed enhanced SARS-CoV-2 neutralization efficacy (25) . However, the lack of an Fc domain may affect serum half-life and manufacturing efficiency, and importantly, optimized designs may allow viral mutational escape due to differences with the endogenous receptor. Plain ACE2-Fc fusions were developed against SARS-CoV-1 in 2003 and were also proposed for SARS-CoV-2 (40, 41) . Recently, a tetravalent ACE2-Fc was described which showed improved neutralization efficiency compared to that of standard ACE2-Fc formats, without ACE2 domain engineering (42) . These ACE2-Fc fusions retained catalytic activity of ACE2 and maintained full Fc effector function.

In contrast to previously reported formats, we developed an ACE2-Fc decoy engineered to be catalytically inactive to prevent systemic activity and with a completely abrogated FcgR interaction to minimize proinflammatory activity. We provided evidence for lack of enzymatic activity on a synthetic substrate while showing that these mutations still maintain reversible engagement with the natural substrate Ang II, avoiding the risk of acting as a substrate sink and offering a safer profile over systemic interference on the renin/angiotensin system. Differently from a previously described ACE2-Fc construct carrying the LALA Fc mutation (43), our design using the LALA-PG mutation shows a complete abrogation of human FcgR engagement while maintaining FcRn interaction to provide extended half-life (30) . Although its relevance has not been conclusively determined for SARS-CoV-2, the engineered Fc should alleviate the risk of antibody-dependent enhancement (ADE) of infection as reportedly mediated through FcgRII for SARS-CoV-1 and MERS-CoV (44, 45) . A cross-reactivity study against a comprehensive panel of close to 6,000 human-soluble and membrane-bound proteins has highlighted the exquisite specificity of this construct for the target protein. Finally, the introduced mutations to inactivate the ACE2 enzymatic activity, which sit outside the S protein-targeting region, maintained affinity and kinetic interactions equivalent to those of the active receptor for the SARS-CoV-2 S1 variants, minimizing the risk of mutational escape.

Despite the enhanced affinity of the S1 variants B.1.1.7 and P.1 for the ACE2 receptor and the increased infectivity of the pseudotyped vectors displaying the D614G, B.1.1.7, and B.1.351 S glycoproteins, the ACE2(HH:NN)-Fc LALA-PG decoy maintained efficient neutralization capacity toward all SARS-CoV-2 variants tested, showing enhanced potency driven by mutational drift. Paradoxically, the spike mutations enhancing affinity for the ACE2 receptor would improve the neutralization potency of ACE2-based decoys. Additionally, we showed binding capacity to SARS-CoV-1 and HCoV-NL63, alongside neutralization of SARS-CoV-1 pseudovirus, providing evidence for broad-spectrum activity over ACE2-tropic viruses.

Conversely, we have observed a substantial drop in neutralization capacity of the LY-CoV555, the 1:1 REGN10933/REGN10987 antibody cocktail, and the latter's individual antibodies for the SARS-CoV-2 variants, in line with previous reports (18) . The LY-CoV555 and REGN10933 were especially impaired by the B.1.351 variant. We also noticed a generally reduced neutralization capacity for the D614G variant, which is likely due to its enhanced infectious capacity compared to that of the Wuhan strain. However, as the lentiviral pseudotyped system adopted in this work has limitations, results could be confirmed in future studies using the authentic virus.

Despite the lack of FcRn engagement in hamster, the i.p. injected ACE2(HH:NN)-Fc LALA-PG showed detectable serum levels for up to 17 days in vivo and was also able to affect the replication of the authentic SARS-CoV-2 virus in a hamster model, reducing body weight loss and lung damage in infected animals.

In conclusion, we describe detailed in vitro and in vivo characterization of a soluble catalytically inactive ACE2-Fc receptor decoy molecule resistant to spike protein mutation. We also demonstrate that our decoy molecule has the potential for rapid upscale manufacturability. In theory, our decoy should be active against any new ACE2-tropic virus which might emerge in the future. In this phase of the SARS-CoV-2 pandemic where viral variants are exerting pressure over the efficacy of vaccines and monoclonal antibodies, the development of biotherapeutics which are inherently resistant to SARS-CoV-2 mutations may be prudent.

Cell line generation and maintenance. HEK-293T cells (ATCC, CRL-11268) were cultured in Iscove's modified Dulbecco's medium (IMDM) (Lonza, 12-726F) supplemented with 10% fetal calf serum (FCS; Biosera, FB 1001/500) and 2 mM GlutaMAX (Gibco, 35050061) at 37°C with 5% CO 2 . Sup-T1 (ATCC, CRL-1942), U937 (ATCC, CRL-1593.2), and K562 (ATCC, CCL-243) were cultured in RPMI 1640 medium (Gibco 21875034) supplemented with 10% fetal calf serum (FCS; Biosera, FB 1001/500) and 2 mM GlutaMAX (Gibco, 35050061) at 37°C with 5% CO 2 .

Sup-T1 cells were g-retrovirally transduced to express the S glycoprotein of SARS-CoV-2 Wuhan Hu-1 strain coexpressed with enhanced blue fluorescent protein (eBFP) as a marker gene. Briefly, 5 Â 10 5 cells were incubated with 1 ml of unquantified vector supernatant in the presence of retronectin in non-tissue culture-treated 24-well plate and subjected to spin-inoculation at 1,000 Â g for 40 min. Cells were recovered 24 h later by culturing in serum-supplemented RPMI 1640 for two passage before use in experiments.

For the generation of MDM, human monocytes were isolated from blood of healthy donors using Easy Sep human monocyte isolation kit (Stemcell, 19359), according to manufacturer's recommendations. Monocyte isolation was determined with the following flow cytometry antibody panel after 10 min incubation with anti-human CD32 (StemCell, 18520): allophycocyanin (APC) anti-human CD14 (Biolegend, 301808), PE-Cy7 anti-human CD3 (Biolegend, 344186), AF488 anti-human CD20 (Biolegend, 302316), and live/dead Sytox Blue stain (Invitrogen, S34857). Monocytes were activated by culturing in Immunocult serum-free macrophage differentiation medium (Stemcell, 10961) supplemented with 50 ng/ml macrophage colony-stimulating factor (M-CSF) (Stemcell, 78057). At day 6, cells were supplemented with 50 ng/ml gamma interferon (IFN-g) (Stemcell, 78020) and 10 ng/ml lipopolysaccharide (LPS) (Sigma, L4391) to stimulate M1 polarization. M1 macrophages were harvested by Accutase dissociation (Stemcell, 07920). The following flow cytometry antibody panel was used to determine monocyte differentiation and M1 polarization after 10 min incubation with anti-human CD32: APC anti-human CD14 (BioLegend, 344186), BV421 anti-human CD80 (BioLegend, 305222), phycoerythrin anti-human CCR7 (BioLegend 353204), APC/Fire750 anti-human CD209 (330116), and 7-aminoactinomycin D (7-AAD) viability staining solution at 5 ml/1 Â 10 6 cells. Samples from both flow staining panels were acquired using the MacsQuant10 instrument (Miltenyi Biotech).

Protein expression, purification, and characterization. Human ACE2 containing amino acids 18 to 740 (UniProt Q9BYF1) was fused to the human IgG1 hinge and Fc (UniProt P01857). Inactive ACE2 was generated by introducing H374N and H378N mutations. Silent Fc variants were generated with L234A/ L235A and L234A/L235A/P329G mutations. Chimeric human inactive ACE2 with hamster Fc fusion was generated using Cricetulus migratorius IgG heavy chain hinge-Fc sequence (GenBank U17166.1). Variable domain sequences for LY-CoV-555 were obtained from published crystal structure PDB 7L3N (31); REGN10933 and REGN10987 sequences were obtained from published crystal structure PDB 6XDG (32) . Heavy variable domains were fused to human IgG1 constant chain (UniProt P01857); kappa variables were fused to human kappa constant domain (UniProt P01834); lambda variable was fused to human lambda constant 1 (UniProt P0CG04). All constructs were cloned in an AbVec vector (46) . REGN10933/REGN10987 antibody cocktail was generated as a 1:1 mix of REGN10933 and REGN10987. Recombinant Fc-tagged proteins were expressed by transient transfection in ExpiCHO, according to manufacturer's recommendations (Thermo Fisher, A29133). Supernatant from transfected CHO cells was purified using 1 ml HiTrap MabSelect PrismA (GE Healthcare, 17549851) affinity chromatography with in-line dialysis in PBS via HiTrap 5 ml desalting columns (GE Healthcare, 29048684) using an Akta Pure system (GE Healthcare), following manufacturer's recommendations.

SARS-CoV-2 S1 domains (amino acids [aa] 1 to 681) from Wuhan (GenBank, QHD43416.1) or including the D614G (11) Journal of Virology reference subtraction to factor for drift. Data were fit to a 1:1 Langmuir binding model using Biacore insight evaluation software (GE Healthcare). SARS-CoV-1 S1 sensograms were also fit to a two-state kinetic model. Since a capture system was used, a local Rmax parameter was used for the data fitting in each case. Viral vector production. Viral vectors were produced by triple transient transfection of HEK-293T cells in 100-mm plates using GeneJuice (Merck, 70967) with a total of 12.5 mg of DNA. g-retroviral vectors were produced by triple transient transfection of 4.69 mg Peq-Pam plasmid (encoding Moloney GagPol), 3.13 mg of RDF plasmid (encoding RD114 envelope), and 4.69 mg retroviral backbone SFG (47) expressing full-length SARS-CoV-2 S glycoprotein coexpressed with eBFP as the marker gene. Similarly, for lentiviral vector production, cells were transfected with 5.42 mg of pCMV-dR8.74 (encoding lentiviral GagPol), 2.92 mg of envelope plasmid expressing codon-optimized SARS-CoV S glycoproteins with their endoplasmic reticulum (ER) retention signals deleted (deletion of the last 19 amino acids on the carboxy terminus), and 4.17 mg of lentiviral backbone pCCL encoding enhanced green fluorescent protein (eGFP) as transgene driven by internal viral spleen focus-forming virus (SFFV) promoter.

Culturing medium was changed 24 h posttransfection, and vector supernatants were collected 48 h after transfection and processed by centrifugation at 1,000 Â g for 10 min at 4°C to remove cellular debris followed by microfiltration using Millex-HV 0.45 mm syringe filter units (Merck, SLHV033RB). Viral supernatants were either kept on ice for further use or frozen down at 280°C for storage.

p24 ELISA. Physical particles were determined by measuring p24 levels using the QuickTitre lentivirus titer, which quantifies lentivirus-associated HIV rather than free p24 proteins (Cell Biolabs, VPK-107-T). Manufacturer's protocol was followed, and samples were assayed in triplicates. Briefly, after incubation with kit's ViraBind reagents and virus inactivation, samples were incubated in microwell plates precoated with anti-p24 antibodies followed by a subsequent incubation with secondary fluorescein isothiocyanate (FITC)-conjugated anti-HIV p24 monoclonal antibody (1:1,000). Subsequently, wells were exposed to HRPconjugated anti-FITC monoclonal antibody (1:1,000). Plates were acquired on a Varioskan Lux instrument at a wavelength of 450 nm. Data were analyzed with Graph Prism 8 (GraphPad software).

SARS-CoV-2 lentiviral pseudotyped viral vector titration. Functional infectious viral titers were determined by flow cytometry analysis (BD LSRFortessa X-20 cell analyzer) of transgene expression in transduced HEK-293T cells that were previously engineered to express human ACE2 and TMPRSS2. Experiments were performed in 24-well plates (50,000 cells/well). Serially diluted viral supernatants were added onto seeded cells in the presence of 8 mg/ml Polybrene. Transduction efficiencies were determined 72 h later using BD LSRFortessa X-20 cell analyzer. eGFP expression between 0.5% and 20% was used in the following equation to determine viral titer: Samples were incubated at 2 to 8°C for 1 h and centrifuged at 2,000 Â g for 10 min at 2 to 8°C. Separated serum was stored at 280°C. ACE2(HH:NN)-Fc LALA-PG concentration was measured via ELISA. Briefly, 96-well plates (Corning Inc., 42592) were coated with anti-human IgG antibody (Sigma-Aldrich, I6260) at 1 mg/ml in 50 ml/well overnight at 4°C. Plates were washed 4 times in PBS 0.05% Tween 20 and blocked with 200 ml/well of blocking buffer (GenScript, DD-PK-009) for 1 h at RT on a shaking platform. Upon wash, plates were incubated with 50 ml/well of test sample diluted 100-fold in assay buffer (GenScript, DD-PK-009) in duplicate for 1 h at RT on a shaking platform. Standard curve was generated using purified ACE2(HH:NN)-Fc LALA-PG at 80 mg/ml with 2-fold serial dilutions in blank hamster serum. Plates were washed as described above and incubated with anti-human Fc HRP-conjugated detection antibody (Jackson ImmunoResearch, 109-035-088) at 1:10,000 dilution in assay buffer for 1 h at RT on a shaking platform. Upon wash, plates were incubated with 100 ml/well of TMB solution (GenScript, DD-PK-009) and blocked with 100 ml/well of stop solution (GenScript, DD-PK-009). Plates were read at 450 nm by using a Multiskan FC plate reader (Thermo Fisher Scientific). Pharmacokinetic parameters were calculated by WinNonlin 8.1 (Certara) with the noncompartmental model (NCA). Syrian hamsters (Mesocricetus auratus) RjHan:AURA strain, male and females 4 to 10 weeks old, were individually caged in a human biosafety level 3 laboratory. At day 0, animals were challenged by intranasal inoculum of 0.1 ml of authentic SARS-CoV-2 with a dose of 10 4.5 TCID 50 under medetomidine and ketamine sedation. At 1 day post-infection (DPI), animals were treated with i.p. injections of 5 mg/kg or 50 mg/kg ACE2(HH:NN)-Fc LALA-PG or PBS, at equal volumes, and monitored until 7 DPI (group n = 6). Nonterminal blood samples were collected at 25 DPI and terminal blood samples were collected at 7 DPI. For human Fc detection, blood samples were inactivated by incubation at 56°C for 2 h before being stored at 220°C. Detection of residual human Fc in the hamster sera was performed by ELISA, using an anti-human Fc MAb (Sigma-Aldrich, I6260) as capture. The standard curve was generated using purified ACE2(HH:NN)-Fc LALA-PG, passed through the same heat-inactivation step as the serum samples and ranging from 22.8 nM to 22.3 pM via a 2-fold serial dilution. Changes relative to ELISA protocol detailed above: Nunc MaxiSorp clear 96-well plates were coated with 1 mg/ml (in PBS) of anti-human Fc MAb overnight at 4°C in 50 ml/well. Plates were blocked with 200 ml/well of PBS 2% BSA for 1 h at RT. Wash steps were performed 3 times in PBS 0.05% Tween 20. Serum samples were tested at both 1:100 and 1:1,000 dilutions in duplicate. Bound proteins were detected with anti-human HRP-conjugated secondary antibody (Jackson ImmunoResearch, 109-035-088) at 1:3,000 dilution in PBS 0.5% BSA. Specific interaction revealed with 1-step TMB Ultra reagent (Thermo Fisher, 34028) at 45 ml/well and blocked with 45 ml/well of 1 M H 2 SO 4 . Plates were acquired on a Varioskan Lux instrument at a wavelength of 450 nm.

Body weight measurements were recorded daily throughout the study. Wheel rotations were counted automatically (4 counts are equal to 1 full rotation) every day between 8:15 and 12:00 a.m. Clinical symptoms were graded depending on severity. Active animals (alert with normal behavior and ,15% body weight loss) were assigned a score of 0. Animals with ruffled fur, curled bodies, nasal/ocular discharge, sneezing/coughing, or mild increased respiratory rate or showing reduced activity were assigned a score of 1. Animals inactive and sluggish, showing abdominal breathing or .20% body weight loss were assigned a score of 2. Animals with passive/absent behavior or with dyspnea were assigned a score of 3. The symptoms were summed in a ranked manner, using the calculation N 0 Â 0 1 N 1 Â 1 1 N 2 Â 2 1 N 3 Â 3 1 N 4 Â 4, where N is the number of animals and the number in subscript indicates the number of symptoms per animal. Throat swabs were collected at 2, 3, 4, 6, and 7 DPI to test for presence of SARS-CoV-2 by qPCR. RNA was isolated using a Direct-zol RNA miniprep kit (Zymo Research, R2056) and subgenomic RNA detected as described previously (48, 49) . Postmortem examinations were performed at 7 DPI. For RNA analysis, lung tissues were homogenized by an Ultra-Turrax homogenizer before RNA extraction and analysis by total viral RNA and subgenomic RNA as described above. Macroscopic lung lesions were assessed by a pathologist according to the following scoring scheme: 0, no macroscopical changes; 1, focal discoloration of lung ,20%; 2, multifocal discoloration of lung 20 to 50%; 3, multifocal discoloration of lung 50 to 80%; 4, whole lung affected .80%. Animal caretakers and pathology personnel were blinded for the treatment groups. Experiments were performed by Wageningen Bioveterinary Research Division Virology of Wageningen University. Animal work was approved by the Dutch Central Authority for Scientific procedures on Animal (CCD), experimental application 2020.D-0007.016 by the Animal Welfare Body of Wageningen University and Research.

Statistical analysis. All statistical analyses were performed using GraphPad Prism 8 (GraphPad Software). Specific analysis is detailed in figure legends. A P value ,0.05 was considered significant.

Supplemental material is available online only. SUPPLEMENTAL FILE 1, XLSX file, 0.1 MB.

This work was funded by the UK Research and Innovation business-led innovation in response to global disruption grant. England/02/2020 isolate of SARS-CoV-2 was kindly provided by Public Health England (PHE), UK. We thank Nadia Oreshkova for helpful discussions and guidance in the in vivo assays.

M.F., S.C.O., and M.P. designed the study. M.F., S.C.O., F.T.I., and R.B. planned and/or performed protein purification and biophysical characterizations. J.S., K.L., K.W., F.P., and C.A. planned and/or performed plasmid design and cloning. L.M., Z.A., and R.K. planned and/or performed lentiviral production and characterization as well as flow cytometry assays. Z.A. and V.B. planned and performed MDM work. L.M., J.S., and P.W. 

Purified proteins were analyzed for purity determination via sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) on a 4 to 20% gradient gel (Bio-Rad, 4568094), with or without the presence of 2-mercaptoethanol as reducing agent. Differential scanning fluorimetry. Thermal stability was determined by nano differential scanning fluorimetry (nanoDSF) on a Prometheus NT.48 instrument (Nanotemper) using first derivative of 350/330 nm ratio to determine the melting temperature (T m ) value. Samples were loaded on a glass capillary and temperature scanned from 20 to 95°C at 1°C/min. Aggregation and particle size measurement. Aggregation propensity and average particle size of the test proteins were determined using a Zetasizer Ultra device and ZS Xplorer software

Enzo Life Science, BML-P163) as the substrate in 96-well black microtiter plates. Samples were diluted in reaction buffer (50 mM 4-morpholineethanesulfonic acid

CDB-H5222) were captured to a density of 50 RU (or 150 RU for FcgRIIa, FcgRIIb, and FcgRIIIb) on flow cell 2, 3, or 4 of a series S CM5 chip (GE Healthcare) functionalized with an anti-His capture kit (GE Healthcare) using a Biacore T200 instrument. HBS-EP1 buffer was used as running buffer in all experimental conditions. Purified ACE2(HH:NN)-Fc, ACE2(HH:NN)-Fc LALA, and ACE2(HH:NN)-Fc LALA-PG at a concentration of 500 nM with 2-fold serial dilutions were used as the analyte and injected over the respective flow cells with 150 s contact time and 300 s dissociation. All experiments were performed at 25°C with a flow rate of 30 ml/ml. Flow cell 1 was unmodified and used for reference subtraction. A "0 concentration" sensogram of buffer alone was used as a double SARS-CoV-2 lentiviral pseudotyped viral vector neutralization assay. Proteins were serially were spin-inoculated at 1,000 Â g for 10 min and incubated for 72 h. Viral titers were then quantified by eGFP expression in target cells using BD LSRFortessa X-20 cell analyzer, and infectivity of all fractions was determined as a percentage of viral titers in the PBS only control. SARS-CoV-2 virus neutralization assay. Vero cells (ATC-CCL81) cultured in Dulbecco's modified Eagle's medium (DMEM) (Sigma, catalog no. D6546) with 10% FCS, 2 mM L-glutamine (Sigma-Aldrich, G7513), and 1% penicillin/streptomycin (Invitrogen, 15140148) were seeded the day prior to infection at 2 Â 10 4 cells per well in a 96-well flat-bottom plate. Serial dilutions of proteins of interest were incubated with 100 TCID 50 of SARS-CoV-2

MAB12183-100) at 1:500 dilution and HRP-conjugated goat anti-mouse IgG antibody (Jackson ImmunoResearch, 115-035-146) at 1:5,000 dilution in 3% wt/vol milk in 0.05% PBS-Tween. Plates were acquired on a BMG FLUOstar Omega at a wavelength of 450 nm. Cell microarray test. A total of 5,477 expression vectors, encoding both ZsGreen1 and a full-length human plasma membrane protein or a cell surface-tethered human secreted protein, and 371 human heterodimers were coarrayed across a microarray slide in duplicate (Table S1). HEK293 cells were used for reverse transfection and expression. Test protein was incubated at 20 mg/ml upon cell fixation. Hits were detected by fluorescent secondary antibody using ImageQuant software (GE Healthcare). An expression vector (pIRES-hEGFR-IRES-ZsGreen1) was spotted in quadruplicate on every slide and used as the transfection control. Assay was performed by Retrogenix Ltd

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China

COVID-19: risk for cytokine targeting in chronic inflammatory diseases?

Characterization of a novel coronavirus associated with severe acute respiratory syndrome

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

The furin cleavage site of SARS-CoV-2 spike protein is a key determinant for transmission due to enhanced replication in airway cells

CoV-AbDab: the coronavirus antibody database

COVID-19 antibody therapeutics tracker: a global online database of antibody therapeutics for the prevention and treatment of COVID-19

A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity

Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus

Emergence and spread of a SARS-CoV-2 variant through Europe in the summer of 2020

Covid-19: new coronavirus variant is identified in UK

Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa

Comprehensive mapping of mutations to the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies

Phylogenetic relationship of SARS-CoV-2 sequences from Amazonas with emerging Brazilian variants harboring mutations E484K and N501Y in the Spike protein

Genomics and Potent Pan-SARS-CoV-2 Neutralizing Receptor Decoy Journal of Virology epidemiology of the P.1 SARS-CoV-2 lineage in Manaus

Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7

Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

VEGF-Trap: a VEGF blocker with potent antitumor effects

Abatacept for rheumatoid arthritis refractory to tumor necrosis factor a inhibition

A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome

Engineered ACE2 receptor traps potently neutralize SARS-CoV-2

De novo design of potent and resilient hACE2 decoys to neutralize SARS-CoV-2

Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2

Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions

COVID-19-associated hyperinflammation and escalation of patient care: a retrospective longitudinal cohort study

Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1

Effector-attenuating substitutions that maintain antibody stability and reduce toxicity in mice

LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection

Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail

Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development

Effects of histidine and sucrose on the biophysical properties of a monoclonal antibody

Development of high concentration protein biopharmaceuticals: the use of platform approaches in formulation development

Retrospective evaluation of low-pH viral inactivation and viral filtration data from a multiple company collaboration

Monoclonal antibodies to disrupt progression of early Covid-19 infection

Prospective mapping of viral mutations that escape antibodies used to treat COVID-19

Retroviruses pseudotyped with the severe acute respiratory syndrome coronavirus spike protein efficiently infect cells expressing angiotensin-converting enzyme 2

Potent neutralization of 2019 novel coronavirus by recombinant ACE2-Ig

A super-potent tetramerized ACE2 protein displays enhanced neutralization of SARS-CoV-2 virus infection

Novel ACE2-IgG1 fusions with improved in vitro and in vivo activity against SARS-CoV2

Anti-severe acute respiratory syndrome coronavirus spike antibodies trigger infection of human immune cells via a pH-and cysteine proteaseindependent Fc R pathway

Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins

Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning

Induction of antigen-specific tumor immunity by genetic and cellular vaccines against MAGE: enhanced tumor protection by coexpression of granulocyte-macrophage colony-stimulating factor and B7-1

Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR

Virological assessment of hospitalized patients with COVID-2019